Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-highest quintile among peers.
Putnam Global Health Care A PHSTX
- NAV / 1-Day Return 65.62 / −0.08 %
- Total Assets 1.9 Bil
-
Adj. Expense Ratio
- Expense Ratio 1.070%
- Distribution Fee Level Low
- Share Class Type Front Load
- Category Health
- Investment Style Large Blend
- Min. Initial Investment 0
- Status Open
- TTM Yield 0.15%
- Turnover 41%
USD | NAV as of Oct 04, 2024 | 1-Day Return as of Oct 04, 2024, 10:29 PM GMT+0
Morningstar’s Analysis PHSTX
Will PHSTX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 61.0
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 10.36 | 201.9 Mil | Healthcare |
UnitedHealth Group Inc | 9.45 | 184.2 Mil | Healthcare |
AbbVie Inc | 7.45 | 145.1 Mil | Healthcare |
AstraZeneca PLC | 6.65 | 129.6 Mil | Healthcare |
Innoviva Inc | 5.28 | 102.9 Mil | Healthcare |
Novo Nordisk AS Class B | 5.04 | 98.1 Mil | Healthcare |
Intuitive Surgical Inc | 5.01 | 97.6 Mil | Healthcare |
Thermo Fisher Scientific Inc | 4.38 | 85.4 Mil | Healthcare |
Johnson & Johnson | 3.71 | 72.3 Mil | Healthcare |
Roche Holding AG | 3.63 | 70.8 Mil | Healthcare |